FindTrial
Sign In

The Impact of Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinoma: A Single Center Experience

The Impact of Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinoma: A Single Center Experience

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20150221001
Enrollment
Unknown
Registered
2015-02-21
Start date
2014-01-16
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma BCLC stage C Hepatocellular carcinoma BCLC stage C TACE Transarterial Chemoembolization

Interventions

Hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer (BCLC) stage C who received TACE
Health Services Research
Hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer (BCLC) stage C

Sponsors

Rajavithi Hospital
Lead Sponsor
Rajavithi Hospital
Collaborator

Eligibility

Sex/Gender
All
Age
0 Years to 0 Years

Inclusion criteria

Inclusion criteria: 1. Advanced HCC patients (BCLC stage C) who received TACE

Exclusion criteria

Exclusion criteria: Child-Pugh score C Patients received chemotherapy Patients received radiation therapy Patients had surgery before TACE

Design outcomes

Primary

MeasureTime frame
median survival time 1 year after intervention Kaplan-Meier method—

Secondary

MeasureTime frame
Procedural related complication 30 day after intervention Percentage—

Countries

Thailand

Contacts

Public ContactNisit Tongsiri

Rajavithi Hospital

nisittongsiri@gmail.com0899447815

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026